Recent advances and future trends in the targeted therapy of metastatic gastric cancer

References

• Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
   PubMed Web of Science ®Google Scholar
• Grabsch HI, Tan P. Gastric cancer pathology and underlying molecular mechanisms. Dig Surg 2013;30(2):150-8
   PubMed Web of Science ®Google Scholar
• Tan IB, Ng I, Tai WM, Tan P. Understanding the genetic basis of gastric cancer: recent advances. Expert Rev Gastroenterol Hepatol 2012;6(3):335-41
   PubMed Web of Science ®Google Scholar
• Schuell B, Gruenberger T, Scheithauer W. Zielinski Ch, Wrba F. HER2/neu protein expression in colorectal cancer. BMC Cancer 2006;6:123
   PubMed Web of Science ®Google Scholar
• Eltze E, Wülfing C, Von Struensee D, et al. Cox-2 and Her2/neu co-expression in invasive bladder cancer. Int J Oncol 2005;26(6):1525-31
   PubMedGoogle Scholar
• McKenzie SJ, DeSombre KA, Bast BS, et al. Serum levels of HER-2 neu (C-erbB) correlate with overexpression of p185(neu) in human ovarian cancer. Cancer 1993;71(12):3942-6
   PubMedGoogle Scholar
• Grávalos C, Gómez-Martín C, Rivera F, et al. Phase II study of trastuzumab. and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Clin Transl Oncol 2011;13(3):179-84
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376(9742):687-97
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, et al. EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367(19):1783-91
   PubMed Web of Science ®Google Scholar
• Barok M, Tanner M, Köninki K, Isola J. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett 2011;306(2):171-9
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011;29(4):398-405
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov identifier: NCT01641939. Available from: http://clinicaltrials.gov/ct2/show/NCT01641939
   Google Scholar
• Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010;28(7):1138-44
   PubMed Web of Science ®Google Scholar
• Fuentes G, Scaltriti M, Baselga J, Verma CS. Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism. Breast Cancer Res 2011;13(3):R54
   PubMedGoogle Scholar
• ClinicalTrials.gov identifier: NCT01461057. Available from: http://clinicaltrials.gov/ct2/show/NCT01461057
   Google Scholar
• Tabernero J, Hoff PM, Shen L, et al. Pertuzumab (P) with trastuzumab (T) and chemotherapy (CTX) in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer: An international phase III study (JACOB). J Clin Oncol 2013;31(Suppl):Abstract TPS4150
   Google Scholar
• Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366(2):109-19
   PubMed Web of Science ®Google Scholar
• Iqbal S, Goldman B, Fenoglio-Preiser CM, et al. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol 2011;22(12):2610-15
   PubMed Web of Science ®Google Scholar
• Hecht JR, Bang YJ, Qin S, et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial. J Clin Oncol 2013;31(Suppl):Abstract LBA4001
   Google Scholar
• Bang YJ. A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population. Tytan study. J Clin Oncol 2012;30(Suppl 34):Abstract 11
   Google Scholar
• Wong TW, Lee FY, Yu C, et al. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin Cancer Res 2006;12(20 Pt 1):6186-93
   PubMedGoogle Scholar
• Nam HJ, Kim HP, Yoon YK. Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer. Cancer Lett 2011;302(2):155-65
   PubMed Web of Science ®Google Scholar
• Nam HJ, Ching KA, Kan J, et al. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer. Mol Cancer Ther 2012;11(2):439-51
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov identifier: NCT01152853. Available from: http://clinicaltrials.gov/show/NCT01152853
   Google Scholar
• Liu L, Wu N, Li J. Novel targeted agents for gastric cancer. J Hematol Oncol 2012;5:31
   PubMedGoogle Scholar
• Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 1990;265(14):7709-12
   PubMed Web of Science ®Google Scholar
• Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 2010;28(28):4390-9
   PubMed Web of Science ®Google Scholar
• Lordick F, Luber B, Lorenzen S, et al. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer 2010;102(3):500-5
   PubMed Web of Science ®Google Scholar
• Han SW, Oh DY, Im SA, et al. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 2009;100(2):298-304
   PubMed Web of Science ®Google Scholar
• Kim C, Lee JL, Ryu MH, et al. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest New Drugs 2011;29(2):366-73
   PubMed Web of Science ®Google Scholar
• Pinto C, Di Fabio F, Barone C, et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer 2009;101(8):1261-8
   PubMed Web of Science ®Google Scholar
• Pinto C, Di Fabio F, Siena S, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007;18(3):510-17
   PubMed Web of Science ®Google Scholar
• Lordick F, Kang YK, Chung HC, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators. Lancet Oncol 2013;14(6):490-9
   PubMed Web of Science ®Google Scholar
• Crosby T, Hurt CN, Falk S, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol 2013;14(7):627-37
   PubMed Web of Science ®Google Scholar
• Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 2013;14(6):481-9
   PubMed Web of Science ®Google Scholar
• Kim YH, Sasaki Y, Lee KH, et al. Randomized phase II study of nimotuzumab, an anti-EGFR antibody, plus irinotecan in patients with 5-fluorouracil-based regimen-refractory advanced or recurrent gastric cancer in Korea and Japan: Preliminary results. J Clin Oncol 2011;29(Suppl 4):Abstract 87
   Google Scholar
• Rao S, Starling N, Cunningham D, et al. Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. Br J Cancer 2008;99(6):868-74
   PubMed Web of Science ®Google Scholar
• Rao S, Starling N, Cunningham D, et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Ann Oncol 2010;21(11):2213-19
   PubMed Web of Science ®Google Scholar
• Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006;24(30):4922-7
   PubMed Web of Science ®Google Scholar
• Rojo F, Tabernero J, Albanell J, et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol 2006;24(26):4309-16
   PubMed Web of Science ®Google Scholar
• Rodriguez CP, Adelstein DJ, Rice TW, et al. A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer. J Thorac Oncol 2010;5(2):229-35
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383(9911):31-9
   PubMed Web of Science ®Google Scholar
• Wilke H, Van Cutsem E, Oh SC, et al. A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxelin the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBB). J Clin Oncol 2014;32(Suppl 3):Abstract LBA7
   Google Scholar
• Uronis HE, Bendell JC, Altomare I, et al. A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. Oncologist 2013;18(3):271-2
   PubMed Web of Science ®Google Scholar
• Shah MA, Jhawer M, Ilson DH, et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011;29(7):868-74
   PubMed Web of Science ®Google Scholar
• El-Rayes BF, Zalupski M, Bekai-Saab T, et al. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol 2010;21(10):1999-2004
   PubMed Web of Science ®Google Scholar
• Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006;24(33):5201-6
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011;29(30):3968-76
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, de Haas S, Kang YK, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012;30(17):2119-27
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov identifier: NCT00450203. Available from: http://clinicaltrials.gov/show/NCT00450203
   Google Scholar
• Li J, Qin S, Xu J, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol 2013;31(26):3219-25
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov identifier: NCT01512745. Available from: http://clinicaltrials.gov/show/NCT01512745
   Google Scholar
• Satoh T, Yamada Y, Muro K, et al. Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer. Cancer Chemother Pharmacol 2012;69(2):439-46
   PubMed Web of Science ®Google Scholar
• Ko AH, Tabernero J, Garcia De Paredes M, et al. Phase II study of telatinib (T) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced cancer of the stomach (G). J Clin Oncol 2010;28(Suppl):Abstract e14575
   Google Scholar
• Kim C, Lee JL, Choi YH, et al. Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. Invest New Drugs 2012;30(1):306-15
   PubMed Web of Science ®Google Scholar
• Martin-Richard M, Gallego R, Pericay C, et al. Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A gemcad study. Invest New Drugs 2013;31(6):1573-9
   PubMed Web of Science ®Google Scholar
• Sun W, Powell M, O‘Dwyer PJ, et al. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010;28(18):2947-51
   PubMed Web of Science ®Google Scholar
• Moehler M, Mueller A, Hartmann JT, et al. An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer 2011;47(10):1511-20
   PubMed Web of Science ®Google Scholar
• Bang YJ, Kang YK, Kang WK, et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs 2011;29(6):1449-58
   PubMed Web of Science ®Google Scholar
• Yi JH, Lee J, Lee J, et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Br J Cancer 2012;106(9):1469-74
   PubMed Web of Science ®Google Scholar
• Gómez-Martín C, Salazar R, Montagut C, et al. A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer. Invest New Drugs 2013;31(2):390-8
   PubMedGoogle Scholar
• Wang Y, Hailey J, Williams D, et al. Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol Cancer Ther 2005;4(8):1214-21
   PubMedGoogle Scholar
• Gao J, Chang YS, Jallal B, Viner J. Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology. Cancer Res 2012;72(1):3-12
   PubMedGoogle Scholar
• Murakami H, Doi T, Yamamoto N, et al. Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2012;70(3):407-14
   PubMed Web of Science ®Google Scholar
• Molife LR, Fong PC, Paccagnella L, et al. The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Br J Cancer 2010;103(3):332-9
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov identifier: NCT01457846. Available from: http://clinicaltrials.gov/show/NCT01457846
   Google Scholar
• ClinicalTrial.gov identifier: NCT01719549. Available from: http://clinicaltrials.gov/show/NCT01719549
   Google Scholar
• Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 2006;12(12):3657-60
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Tang LH, Coit DG, et al. MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev 2011;20(5):1021-7
   PubMed Web of Science ®Google Scholar
• Lennerz JK, Kwak EL, Ackerman A, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011;29(36):4803-10
   PubMed Web of Science ®Google Scholar
• Kawakami H, Okamoto I, Arao T, et al. MET amplification as a potential therapeutic target in gastric cancer. Oncotarget 2013;4(1):9-17
   PubMedGoogle Scholar
• Iveson T, Donehower RC, Davidenko I, et al. Safety and efficacy of epirubicin, cisplatin, and capecitabine (ECX) plus rilotumumab (R) as first line treatment for unresectable locally advanced (LA) or metastatic (M) gastric (G) or esophagogastric junction (EGJ) adenocarcinoma. Eur J Cancer 2011;47:Suppl 1
   Google Scholar
• Oliner KS, Tang R, Anderson A, et al. Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. J Clin Oncol 2012;30(Suppl):Abstract 4005
   Google Scholar
• ClinicalTrials.gov identifier: NCT01697072. Available from: http://clinicaltrials.gov/show/NCT01697072
   Google Scholar
• ClinicalTrials.gov identifier: NCT01662869. Available from: http://clinicaltrials.gov/show/NCT01662869
   Google Scholar
• Fasolo A, Sessa C, Gianni L, Broggini M. Seminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologist. Ann Oncol 2013;24(1):14-20
   PubMedGoogle Scholar
• Shah MA, Wainberg ZA, Catenacci DV, et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS ONE 2013;8(3):e54014
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Ducreux M, Ohtsu A. mTOR as a therapeutic target in patients with gastric cancer. Int J Cancer 2012;130(3):491-6
   PubMed Web of Science ®Google Scholar
• Okamoto I, Doi T, Ohtsu A, et al. Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors. Jpn J Clin Oncol 2010;40(1):17-23
   PubMed Web of Science ®Google Scholar
• Werner D, Atmaca A, Pauligk C, et al. Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma. Cancer Med 2013;2(3):325-33
   PubMed Web of Science ®Google Scholar
• Doi T, Muro K, Boku N, et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 2010;28(11):1904-10
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Ajani JA, Bai YX, et al. Everolimus for Previously Treated Advanced Gastric Cancer: results of the Randomized, Double-Blind, Phase III GRANITE-1 Study. J Clin Oncol 2013;31:3935-43
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov identifier: NCT01248403. Available from: http://clinicaltrials.gov/show/NCT01248403
   Google Scholar
• Wang RE. Targeting heat shock proteins 70/90 and proteasome for cancer therapy. Curr Med Chem 2011;18(27):4250-64
   PubMedGoogle Scholar
• Wang J, Cui S, Zhang X, et al. High expression of heat shock protein 90 is associated with tumor aggressiveness and poor prognosis in patients with advanced gastric cancer. PLoS ONE 2013;8(4):e62876
   PubMed Web of Science ®Google Scholar
• Pick E, Kluger Y, Giltnane JM, et al. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res 2007;67(7):2932-7
   PubMed Web of Science ®Google Scholar
• Solit DB, Scher HI, Rosen N. Hsp90 as a therapeutic target in prostate cancer. Semin Oncol 2003;30(5):709-16
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov identifier: NCT01613950. Available from: http://clinicaltrials.gov/show/NCT01613950
   Google Scholar
• Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 2005;23(21):4776-89
   PubMed Web of Science ®Google Scholar
• Fujita T, Doihara H, Washio K, et al. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells. Anticancer Drugs 2007;18(6):677-86
   PubMedGoogle Scholar
• Jatoi A, Dakhil SR, Foster NR, et al. Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B). J Thorac Oncol 2008;3(5):516-20
   PubMedGoogle Scholar
• Shah MA, Power DG, Kindler HL, et al. A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. Invest New Drugs 2011;29(6):1475-81
   PubMedGoogle Scholar
• Le TV, Suh JH, Kim N, Park HJ. In silico identification of poly(ADP-ribose)polymerase-1 inhibitors and their chemosensitizing effects against cisplatin-resistant human gastric cancer cells. Bioorg Med Chem Lett 2013;23(9):2642-6
   PubMedGoogle Scholar
• Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modular of chemotherapy-induced apoptosis. Cancer Res 2003;63(19):6221-8
   PubMed Web of Science ®Google Scholar
• Gilardini Montani MS, Prodosmo S, Stagnis V, et al. ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition. J Exp Clin Res 2013;32(1):95
   PubMed Web of Science ®Google Scholar
• Bang YJ, Im SA, Lee KW, et al. Olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer: a randomized, double-blind phase II study. Clin Oncol 2013;31(Suppl):Abstract 4013
   Google Scholar
• Fu J, Bian M, Jiang Q, Zhang C. Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 2007;5(1):1-10
   PubMed Web of Science ®Google Scholar
• Katsha A, Soutto M, Sehdev V, et al. Aurora kinase a promotes inflammation and tumorigenesis in mice and human gastric neoplasia. Gastroenterology 2013;145(6):1312-22. e8
   PubMedGoogle Scholar
• Sehdev V, Soutto M, Belkhiri A, et al. Effect of a combination of aurora kinase A inhibitor MNL-8237 and cisplatin on gastrointestinal tumors. J Clin Oncol 2012;30(Suppl 4)):Abstract 58
   Google Scholar
• Robert F, Verschraegen C, Hurwitz H, et al. A phase I trial of sns-314, a novel and selective pan-aurora kinase inhibitor, in advanced solid tumor patients. J Clin Oncol 2009;27:15s ( Suppl Abstract 2536
   Google Scholar
• Arkenau HT, Plummer R, Molife LR, et al. A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Ann Oncol 2012;23(5):1307-13
   PubMedGoogle Scholar
• Medema RH, Lin CC, Yang JC. Polo-like kinase 1 inhibitors and their potential role in anticancer. Clin Cancer Res 2011;17(20):6459-66
   PubMedGoogle Scholar
• Kanaji S, Saito H, Tsujitani S, et al. Expression of polo-like kinase 1 (PLK1) protein predicts the survival of patients with gastric carcinoma. Oncology 2006;70(2):126-33
   PubMedGoogle Scholar
• Weichert W, Ullrich A, Schmidt M, et al. Expression patterns of polo-like kinase 1 in human gastric cancer. Cancer Sci 2006;97(4):271-6
   PubMedGoogle Scholar
• Mross K, Dittrich C, Aulitzky WE, et al. A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network. Br J Cancer 2012;107(2):280-6
   PubMed Web of Science ®Google Scholar
• Hofheinz RD, Al-Batran SE, Hochhaus A, et al. An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. Clin Cancer Res 2010;16(18):4666-74
   PubMed Web of Science ®Google Scholar
• Schwartz GK, Ilson D, Saltz L, et al. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001;19(7):1985-92
   PubMed Web of Science ®Google Scholar
• Rathkopf D, Dickson MA, Feldman DR, et al. Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors. Clin Cancer Res 2009;15(23):7405-11
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov identifier: NCT00991952. Available from: http://clinicaltrials.gov/show/NCT00991952
   Google Scholar
• Janjigian YY, Tang LH, Shibata S, et al. A multicenter random assignment phase II study of irinotecan and flavopiridol versus irinotecan alone for patients with p53 wild-type gastric adenocarcinoma (NCI 8060). J Clin Oncol 2012;30(Suppl)):Abstract e14586
   Google Scholar
• Al-Batran SE, Pauligk C, Wirtz R, et al. The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer. Ann Oncol 2012;23(7):1699-705
   PubMedGoogle Scholar
• Ahn GO, Brown JM. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 2008;13(3):193-205
   PubMed Web of Science ®Google Scholar
• Hiratsuka S, Nakamura K, Iwai S, et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002;2(4):289-300
   PubMed Web of Science ®Google Scholar
• Bramhall SR, Hallissey MT, Whiting J, et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 2002;86(12):1864-70
   PubMed Web of Science ®Google Scholar
• Cheng J, Fan XM. Role of cyclooxygenase-2 in gastric cancer development and progression. World J Gastroenterol 2013;19(42):7361-8
   PubMed Web of Science ®Google Scholar
• Sahin IH, Hassan MM, Garrett CR. Impact of non-steroidal anti-inflammatory drugs on gastrointestinal cancers: current state-of-the science. Cancer Lett 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Wong BC, Zhang L, Ma JL, et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut 2012;61(6):812-18
   PubMed Web of Science ®Google Scholar
• Wang WH, Huang JQ, Zheng GF, et al. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2003;95(23):1784-91
   PubMedGoogle Scholar
• Zaridze D, Borisova E, Maximovitch D, Chkhikvadze V. Aspirin protects against gastric cancer: results of a case-control study from Moscow, Russia. Int J Cancer 1999;82(4):473-6
   PubMedGoogle Scholar
• Thun MJ, Namboodiri MM, Calle EE, et al. Aspirin use and risk of fatal cancer. Cancer Res 1993;53(6):1322-7
   PubMed Web of Science ®Google Scholar
• Altorki NK, Christos P, Port JL, et al. Preoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: results of a phase 2 trial. J Thorac Oncol 2011;6(6):1121-7
   PubMedGoogle Scholar
• Toomey PG, Vohra NA, Ghansah T, et al. Immunotherapy for gastrointestinal malignancies. Cancer Control 2013;20(1):32-42
   PubMedGoogle Scholar
• Jäger M, Schoberth A, Ruf P, et al. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. Cancer Res 2009;69(10):4270-6
   PubMedGoogle Scholar
• ClinicalTrials.gov identifier: NCT01569412. Available from: http://clinicaltrials.gov/show/NCT01569412
   Google Scholar
• Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 2010;127(9):2209-21
   PubMed Web of Science ®Google Scholar
• Türeci O, Koslowski M, Helftenbein G, et al. Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. Gene 2011;481(2):83-92
   PubMedGoogle Scholar
• Sahin U, Koslowski M, Dhaene K, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res 2008;14(23):7624-34
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov identifier: NCT01630083. Available from: http://clinicaltrials.gov/show/NCT01630083
   Google Scholar
• Schuler MH, Zvirbule Z, Lordick F, et al. Safety, tolerability, and efficacy of the first-in-class antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomas. J Clin Oncol 2013;31: Suppl Abstract 4080
   Google Scholar
• Shi L, Zhou Q, Wu J, et al. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother 2012;61(12):2251-9
   PubMed Web of Science ®Google Scholar
• Kono K, Takahashi A, Sugai H, et al. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res 2002;8(11):3394-400
   PubMed Web of Science ®Google Scholar
• Burkitt MD, Varro A, Pritchard DM. Importance of gastrin in the pathogenesis and treatment of gastric tumors. World J Gastroenterol 2009;15(1):1-16
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov identifier: NCT00020787. Available from: http://clinicaltrials.gov/show/NCT00020787
   Google Scholar
• Lei Z, Tan IB, Das K, et al. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology 2013;145(3):554-65
   PubMed Web of Science ®Google Scholar